Stock·NYSE·Healthcare
agilon health, Inc. (AGL)
- Market cap
- $1.43B
- Dividend yield
- 0.00%
- Street target
- $115.00median of 15 analysts
- 52-week range
- $7.48 $133.04
The short version
Where AGL stands today, in four lines, and what CleaRank Financial AI makes of it.
AGL at a glance
agilon health, Inc. (AGL): Hold, 53/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($61.57 and $88.57).
- Earnings AGL beat estimates in 1 of its last 7 quarters, yet fell the next day after every one of them.
- Insiders Insiders bought $352K and made no open-market sales over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
AGL carries a CleaRank rating of Hold and a model score of 53/100.
Trend contributes most to that score, with the price 38.24% above its 200-day average and the 50-day average 43.84% above the 200-day. Valuation is the largest drag, because the company lost money and has no meaningful P/E. The 50-day average is $88.57 and the 200-day is $61.57. Across the past year, the price climbed 252.83%.
Only on CleaRank
Figures we compute ourselves from AGL's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $85.12 is 3.9% below the 50-day simple moving average of $88.57.Price above its 200-day average ›
The price is 38.2% above the 200-day simple moving average of $61.57.50-day average above the 200-day ›
The 50-day average ($88.57) is 43.8% above the 200-day average ($61.57), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 62% of its 52-week range, between $7.48 and $133.04.
AGL share price
Pick a period: each tab shows how far AGL has moved over it, to the last close.
Today's trading
Where AGL sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 0.24 is 92.9% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-251.2M on revenue of $5.9B, a net margin of -4.2%.Beat estimates in most recent reports ›
AGL beat the EPS estimate in 1 of its last 7 reports.
Key statistics
The headline figures for AGL.
As of October 17, 2026, AGL trades at $85.12, with a market value of $1.43B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of AGL's valuation, growth and risks.
A P/E cannot be read for agilon health, Inc. (AGL): it is not meaningful, because the company lost money over the last 12 months. AGL trades at 0.24 times its sales, 92.9% below the sector median of 3.4. The company has a market capitalisation of $1.4B and trailing earnings of -$15.41 a share.
The company is losing money, with a net margin of -3.92% and an operating margin of 1.30%. With revenue growth of 7.20%, AGL is 0.9 percentage points slower than the sector median of 8.1%. It reports a return on equity of -78.94%, below the sector median of 7.3%. The balance sheet rounds out the picture, with debt-to-equity of 0.15.
AGL reported $2.15 a share in the August 5, 2026 report, compared with a $0.27 estimate, a beat of 696.30%. Even so, the stock fell 19.49% in the following session.
AGL beat estimates in 1 of the last 7 reports, but the stock fell in the first session after that beat. The August 4, 2025 report is the most striking of the earlier results. EPS missed the estimate by 136.84%, and the stock dropped 51.52% afterward. For this fiscal year, analysts' consensus EPS estimate is -$1.79, and for next year it is $2.36.
AGL typically moves 3.09% on a given day, measured as the 30-day standard deviation of its daily returns. The price sits 36.02% below the 52-week high of $133.04.
AGL against the Healthcare sector
How AGL compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, AGL trades at 0.2414x, far below the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, AGL has lost 23.7% against a gain of 31.6% for XLV.
Performance against XLV
AGL and the Healthcare sector fund over the same days.
Revenue and earnings
How much AGL sells, and how much of it becomes profit.
Revenue growth: Revenue fell 2.1% in FY2025 to $5.9B, from $6.1B a year earlier.
Profit margin: The net margin was -6.6% in FY2025, down from -4.3% the year before.
Loss-making: AGL lost $391M in FY2025.
Earnings reality check
Did AGL beat what analysts expected, and how did the stock react?
Earnings record: AGL beat the analyst estimate in 1 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 1 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $0.27 | $2.15 | +696.30% | -19.49% | -20.02% |
| Feb 25, 2026after close | -$6.85 | -$8.95 | -30.66% | +19.00% | +39.80% |
| Nov 4, 2025after close | -$3.36 | -$6.40 | -90.48% | +4.14% | -14.50% |
| Aug 4, 2025after close | -$2.66 | -$6.30 | -136.84% | -51.52% | -52.45% |
| May 6, 2025after close | $0.16 | -$0.21 | -231.25% | -23.99% | -39.46% |
| Feb 25, 2025after close | -$5.32 | -$6.25 | -17.48% | -7.44% | -12.67% |
| Nov 7, 2024after close | -$2.14 | -$6.98 | -226.17% | -34.05% | -38.71% |
As of October 17, 2026, AGL has beaten the analyst EPS estimate in 1 of its last 7 reported quarters and fell in the first trading session after it; its latest report, on August 5, 2026, came in 696.30% above the estimate and the stock moved -19.49% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 48.1, in neutral territory.RSI above 50 ›
An RSI of 48.1 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of AGL
The score, the reasoning behind it, and what could move the price next.
The trend signal for AGL is mixed. At $85.12, the stock sits 3.89% below its 50-day average of $88.57, yet 38.24% above its 200-day average of $61.57. The 50-day average is 43.84% above the 200-day, but the price has slipped beneath the shorter average. Inside its 52-week range of $7.48 to $133.04, the price is at 62% of the range and 36.02% below the high.
A recent pullback sits inside a stronger longer record: the price fell 5.06% over the past month, fell 34.44% over the past three months and rose 252.83% over the past year. Volume in the last session ran 32.5% below its average, on a day the price fell 3.76%. The 14-day RSI of 48.1 is in the neutral zone, and the MACD line is negative.
Analyst upgrade ›
Bernstein upgraded it to Outperform from Market Perform on September 15, 2026.
Source: Analyst action, Bernstein, September 15, 2026Analyst upgrade ›
Citigroup upgraded it to Neutral from Sell on August 11, 2026.
Source: Analyst action, Citigroup, August 11, 2026
Earnings beat ›
The August 5, 2026 report beat the EPS estimate by 696.30%, and the share price fell 19.49% in the first session after it.
Source: Earnings report, August 5, 2026
- Keep an eye on the two closest levels: the 20-day EMA at $85.46 sits above the price, and the 200-day SMA at $61.57 sits below it.
- AGL's 14-day RSI is 48.1, which is neutral, and its MACD line is negative. Readings above 70 or below 30 point to stretched momentum.
- The share price fell 19.49% in the first session after the August 5, 2026 report. AGL has beaten estimates in 1 of the last 7 reports.
AGL's trend is mixed. The price sits above its 200-day average of $61.57 but below its 50-day average of $88.57. A close above the 50-day would turn both signals higher, while a close below the 200-day would turn both lower. The closest support is the 200-day SMA at $61.57, and the closest resistance is the 20-day EMA at $85.46.
A 14-day RSI of 48.1 places AGL in neutral territory, in the 40 to 60 band.
Technical indicators
Momentum and trend for AGL, from its daily closes.
As of October 17, 2026, with AGL at $85.12, its 14-day RSI is 48.1 (neutral territory), its 50-day simple moving average is $88.57 and its 200-day is $61.57.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What AGL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, AGL's 1-year correlation of daily returns is +0.11 with S&P 500 (SPY), +0.10 with Nasdaq 100 (QQQ), +0.23 with Bitcoin (BTC) and +0.11 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
5 of 15 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $115.00 is 35.1% above the price.More buy ratings than three months ago ›
5 of 15 rate it a buy now, against 4 of 17 three months ago.
AGL Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 15, 2026 | Bernstein | Upgrade | Outperform |
| Aug 24, 2026 | JP Morgan | Maintains | Underweight |
| Aug 11, 2026 | Wells Fargo | Maintains | Overweight |
| Aug 11, 2026 | Citigroup | Upgrade | Neutral |
| Aug 6, 2026 | Truist Securities | Maintains | Hold |
| Aug 6, 2026 | Benchmark | Maintains | Buy |
As of October 17, 2026, 15 Wall Street analysts cover AGL: 5 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $85.00 to $146.00, with a median of $115.00, 35.1% above the price of $85.12.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
AGL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
AGL moves about 3.1% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much AGL tends to move, against the market and on its own.
The long record
AGL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 3.09% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 99.3%, from June 2021 to March 2026; the price is still 92.1% below that peak.Most 1-year holds ended higher ›
18% of 1-year holding periods in the last 6 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in April 2021 is now worth $1,098.32, against $19,745 in the S&P 500 (SPY).
AGL Drawdowns & Recovery
As of October 17, 2026, AGL's worst peak-to-trough fall over the last 6 years with dividends reinvested was -99.3% (June 2021 to March 2026); it is still 92.1% below that peak, and 18% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into AGL in April 2021 is worth now, against the same amount in the S&P 500.
Against the market: AGL trailed the S&P 500 over this period: $1,098.32 against $19,745.
A $10,000 investment in AGL in April 2021 would be worth about $1,098 today with dividends reinvested, compared with about $19,745 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to AGL, and which have not.
Strongest month, April: an average of +46.23%, up in 2 of 5 years.
Weakest month, November: an average of -21.05%, up in 0 of 5 years.
This month, October: has averaged -13.40%, up in 0 of 5 years. Past seasonality does not repeat on schedule.
Over the last 6 years, AGL's strongest calendar month has been April (average +46.23%, up in 2 of 5 years) and its weakest November (average -21.05%, up in 0 of 5 years).
Average return for each calendar month over the last 6 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in AGL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AGL today could grow to about $3,263 by 2036 in the base case, with a 90th-percentile outcome near $24,754 and a 10th-percentile outcome around $430. Projections are statistical simulations, not guarantees.
AGL Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $54.38 for AGL by 2030 in the base case, from $85.12 today (0.6x over 4 years). The 10th-percentile path ends near $15.10. These are outcomes of a Monte Carlo simulation run on AGL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $40.10 | $76.10 | $144 | |
| 2028 | $27.49 | $68.04 | $168 | |
| 2029 | $20.05 | $60.83 | $185 | |
| 2030 | $15.10 | $54.38 | $196 | |
| 2031 | $11.60 | $48.62 | $204 |
Method: a lognormal simulation of AGL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
AGL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $352K on the open market.
As of October 17, 2026, AGL insiders reported no open-market sales and 2 open-market purchases worth $352K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Silvana Battaglia
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Sharad S. Mansukani
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Diana L Mckenzie
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Karen Mcloughlin
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Ronald A Williams
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | John William Wulf
Director
|
Grant | 2.1K | - |
| May 7, 2026 | Timothy Patrick O'Rourke
Chief Executive Officer
|
Grant | 320.0K | - |
| Apr 1, 2026 | Timothy Gertsch
Officer
|
Grant | 10.0K | - |
| Apr 1, 2026 | Jeffrey A Schwaneke
Chief Financial Officer
|
Grant | 75.0K | - |
| Apr 1, 2026 | Benjamin Shaker
Officer
|
Grant | 70.0K | - |
| Apr 1, 2026 | Girish Venkatachaliah
Chief Technology Officer
|
Grant | 28.0K | - |
| Apr 1, 2026 | Denise Zamore
Officer
|
Grant | 50.0K | - |
| Mar 9, 2026 | Benjamin Shaker
Officer
|
Grant | 18.4K | - |
| Mar 9, 2026 | Girish Venkatachaliah
Chief Technology Officer
|
Grant | 18.4K | - |
| Mar 9, 2026 | Denise Zamore
Officer
|
Grant | 5.5K | - |
| Mar 2, 2026 | Benjamin Shaker
Officer
|
Buy | 500.0K | $301.1K |
| Jan 9, 2026 | Jeffrey A Schwaneke
Chief Financial Officer
|
Grant | 600.0K | - |
| Nov 12, 2025 | John William Wulf
Director
|
Buy | 81.0K | $50.9K |
| May 28, 2025 | Silvana Battaglia
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Sharad S. Mansukani
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Diana L Mckenzie
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Karen Mcloughlin
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Ronald A Williams
Director
|
Grant | 78.7K | - |
| May 28, 2025 | John William Wulf
Director
|
Grant | 78.7K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.